本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：872925 证券简称：锦好医疗 公告编号：2024-072 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于近日收到 1项欧盟 医疗器械法规（Medical Device REGULATION（EU）2017/745，简称"MDR"） 认证证书，现将有关情况公告如下： 惠州市锦好医疗科技股份有限公司 一、MDR 认证证书主要内容 关于公司产品获得欧盟 MDR 认证的公告 证书编号：CN24/00005770 上述产品的市场销售可能会受到欧盟法规政策、市场环境变化、以及汇率波 动等不确定因素的影响，公司尚无法预测其对公司未来业绩的具体影响。敬请广 大投资者谨慎投资、注意投资风险。 证书签批时间：2024-09-09 证书到期时间：2029-09-09 二、对公司的影响 Medical Devices Regulation（EU）2017/745（MDR）是欧盟最新医疗器械 法规。公司助听器产品此次获得欧盟 MDR 认证，表明其符合欧盟最新医疗 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-071 惠州市锦好医疗科技股份有限公司 2022 年股权激励计划部分股票期权注销完成公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 在 2022 年股权激励计划实施期间，7 名股票期权激励对象因个人原因主动离职， 以上人员不再具备激励资格，其已获授但尚未行权的股票期权 61,383 份（其中首次授 予部分股票期权 55,803 份，预留部分股票期权 5,580 份）应由公司注销。 2、股票期权注销情况 （1）期权简称及代码：锦好 JLC1 850032；锦好 JLC2 850057 （2）注销数量：61,383 份 （3）剩余已授出的期权数量：527,732 份 二、对公司财务状况的影响 本次注销 2022 年股权激励计划部分股票期权，符合《监管指引第 3 号》和《2022 年激励计划》的相关规定，不存在损害公司及全体股东利益和违反有关法律、法规的 强制性规定的情形，不会对公司的财务状况和经营成果产生重大影响，也不会对公司 股权激励计划 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2][55]. Core Insights - The company, JinHao Medical, has established itself as a leading domestic hearing aid manufacturer since its inception in 2011, achieving significant milestones including multiple high-tech honors and successful listings on the Beijing Stock Exchange in 2021 [2][8]. - Despite facing short-term performance pressures, the company is expected to see results from its self-branded products and channel development in the second half of 2024 [2][29]. - The company has a clear and stable shareholding structure, with the actual controller holding over 60% of the shares, which enhances management stability and investor confidence [2][15]. - JinHao Medical's core business is hearing aids, accounting for over 80% of its revenue, with strong international sales and partnerships with major global retailers [2][17]. - The global hearing aid market is projected to reach USD 8.33 billion by 2025, with a compound annual growth rate (CAGR) of 5.18%, driven by increasing demand due to aging populations [2][45]. - The company aims to strengthen its position in the ODM and self-branded hearing aid markets, focusing on research and development to enhance competitiveness [2][29]. Summary by Sections Company Overview - JinHao Medical focuses on the research, production, and sales of hearing aids, with a significant portion of its revenue derived from this segment [2][17]. - The company has developed its own chip technology, which is expected to reduce costs and improve product competitiveness [2][9]. Industry Overview - The hearing aid industry is experiencing steady growth, driven by an aging population and increasing awareness of hearing health [2][40]. - The domestic market for hearing aids is still developing, with significant potential for growth as local companies like JinHao Medical expand their market share [2][46]. Financial Forecast and Valuation - The company is projected to generate revenues of CNY 141.46 million, CNY 159.88 million, and CNY 181.42 million for the years 2024, 2025, and 2026, respectively, with expected growth rates of -19.11%, 13.02%, and 13.47% [2][51]. - The forecasted net profit for the same period is CNY 2.24 million, CNY 15.52 million, and CNY 17.09 million, reflecting a significant recovery in profitability by 2025 [2][51]. - The current market valuation corresponds to a price-to-earnings (P/E) ratio of 468, 68, and 61 for the years 2024, 2025, and 2026, respectively [2][55].

证券代码：872925 证券简称：锦好医疗 公告编号：2024-070 惠州市锦好医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | | 带法律责任。 | | 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 (2024 年广东辖区上市公司投资者关系管理月投资者集体接待日活 动) 二、 投资者关系活动情况 活动时间：2024 年 9 月 12 日 活动地点：公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 用网络远程的方式回答投资者的提问 参会单位及人员：通过网络方式参加公司 2024 年广东辖区上市公司投资者 关系管理月投资者集体接待日活动的投 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-067 惠州市锦好医疗科技股份有限公司 第三届董事会第五次会议决议公告 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 9 月 6 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2024 年 9 月 3 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 二、议案审议情况 （一）审议通过《关于公司及全资孙公司向 IntriCon Inc.及其关联公司购买资产 议案》 1.议案内容： 具体内容详见公司同日在北京证券交易所指定披露平台（www.bse.cn）披露 的《购买资产公告》（公告编号：2024-068）。 2.议案表决结果：同意 7 票；反对 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-068 惠州市锦好医疗科技股份有限公司 购买资产的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本次交易不构成关联交易。 一、交易概况 （一）基本情况 惠州市锦好医疗科技股份有限公司（以下简称"公司"）及全资孙公司 （inHearing Technology Inc）拟向 IntriCon Inc.及其关联公司购置有关听力健康业 务的芯片、助听器、设备和无形资产，并签署相关购销合同，购销合同总金额为 525 万美元。 inHearing Technology Inc.成立于 2024 年 8 月 13 日，注册地为美国明尼苏达 州，系公司通过全资子公司锦好国际（香港）有限公司 100%持股的公司，未来 将作为公司收购 IntriCon Inc.助听器芯片业务后在境外地区开展芯片业务的主 体，主要负责原 IntriCon Inc.在美国、欧洲等境外地区的助听器芯片业务。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 公司购 ...

Compliance and Certifications - In February 2024, the company passed the on-site audit by KTC, the largest certification body in South Korea, achieving compliance with 72 audit items, allowing its hearing aid products to enter the South Korean market[2]. - In April 2024, the company was recognized as the "Guangdong Province Digital Hearing Aid Engineering Technology Research Center," marking its acknowledgment in independent research and development by the Guangdong Provincial Department of Science and Technology[2]. - In June 2024, the company successfully completed the MDSAP annual audit, which is recognized by regulatory agencies from the USA, Australia, Brazil, Canada, and Japan[3]. - The company has obtained various certifications, including FDA and CE, and is in the final review stage for MDR certification[26][27]. Financial Performance - The company's operating revenue for the current period is CNY 63,314,067.93, a decrease of 37.19% compared to the same period last year[16]. - The net profit attributable to shareholders of the listed company is a loss of CNY 4,573,067.94, representing a decline of 130.25% year-on-year[16]. - The total assets at the end of the current period amount to CNY 419,181,332.03, showing a slight decrease of 0.04% from the previous year[17]. - The total liabilities increased by 28.19% to CNY 70,537,915.71 compared to the previous year[17]. - The company achieved a net cash flow from operating activities of CNY 8,592,945.31, down 62.49% from the previous year[19]. - The company's total revenue for the reporting period was CNY 63.31 million, with overseas revenue accounting for CNY 53.87 million, representing 85.09% of total sales[60]. - The company reported a total revenue of CNY 822,416.66 with a net profit of CNY 22,060.29, indicating a challenging financial period[49]. Research and Development - Research and development expenses for the period were CNY 1,098.84 million, accounting for 17.36% of total revenue[26]. - The company showcased multiple new products at CES 2024 in Las Vegas, highlighting its innovation and R&D capabilities as a Chinese technology enterprise[3]. - The company anticipates that the OTC hearing aid proposal by the FDA will create new market opportunities and enhance global penetration rates for hearing aids[30]. - The company has invested in product research and market expansion, achieving certain results to adapt to market changes and improve profitability[59]. Market and Sales - The overseas sales revenue accounts for approximately 85% of the company's main business income, indicating strong competitiveness in international markets[23]. - The online self-owned brand business has seen significant growth, with revenue from cross-border BTC business reaching CNY 641.64 million, an increase of 168.35% year-on-year[25]. - The company is actively expanding its market presence and developing new sales channels, which are expected to yield incremental orders[56]. - The company faced challenges due to reduced demand from European and American markets, leading to a decrease in overall revenue[55]. Shareholder and Equity Information - The total share capital of the company is 97,686,643 shares after the cancellation of part of the restricted stock from the 2022 equity incentive plan[15]. - The company's major shareholder is Wang Min, who also serves as the actual controller[11]. - The company has approved an employee stock ownership plan to incentivize staff and align their interests with the company's performance[63]. - The top ten shareholders hold a total of 70,177,242 shares, representing 71.8393% of the total shares[70]. Employee and Social Responsibility - The company has absorbed 54 employees from impoverished areas as part of its social responsibility initiatives[53]. - The company plans to optimize its talent pool and implement an employee stock ownership plan to retain key personnel[77]. - Total employees decreased from 407 to 383, with a net reduction of 24 employees during the period[76]. Risk Management and Outlook - The company has not disclosed any major risks related to delisting, indicating a stable operational outlook[7]. - The company has not experienced cumulative losses that cannot be compensated during the reporting period[55]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next six months[106]. Corporate Governance - The board of directors consists of 7 members, while the supervisory board has 3 members[72]. - The company has appointed new executives, including a CFO and a CTO, with terms starting from December 22, 2023, to December 21, 2026[72]. - There were no changes in the controlling shareholder or actual controller during the reporting period[71]. Accounting and Financial Policies - The financial statements are prepared based on the accrual basis of accounting in accordance with the relevant accounting standards[106]. - The company has not made any significant changes to its accounting policies or estimates compared to the previous financial statements[102]. - The company recognizes revenue when control of goods or services is transferred to customers, either at a specific point in time or over a period, depending on contract terms[130].

证券代码：872925 证券简称：锦好医疗 公告编号：2024-060 惠州市锦好医疗科技股份有限公司 第三届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯方式相结合 4.发出监事会会议通知的时间和方式：2024 年 8 月 16 日 以书面方式发出 5.会议主持人：王敏先生 本次会议的召集、召开与表决符合《公司法》等相关法律、法规和《公司章 程》的规定，会议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于<2024 年半年度报告>及<2024 年半年度报告摘要>的议案》 1.议案内容： 根据相关法规及公司章程的规定，公司编制了《2024 年半年度报告》及《2024 年半年度报告摘要》，具体内容详见公司同日在北京证券交易所信息披露平台 (www.bse ...

法律意见书 北京大成（广州）律师事务所 关于惠州市锦好医疗科技股份有限公司 2022 年股票期权与限制性股票激励计划 注销部分股票期权、调整首次授予及预留授予股票 期权行权价格的 法律意见书 www.dentons.com 广州市天河区珠江东路 6 号广州周大福金融中心 14 层、15 层 电话：+86 20 8527 7000 传真：+86 20 8527 7002 二〇二 四 年八月 法律意见书 关于惠州市锦好医疗科技股份有限公司 2022 年股票期权与限制性股票激励计划 注销部分股票期权、调整首次授予及预留授予股票期权行权价格的 法律意见书 致：惠州市锦好医疗科技股份有限公司 北京大成（广州）律师事务所（以下简称"本所"）接受惠州市锦好医疗科技 股份有限公司（以下简称"锦好医疗"或者"公司"）的委托，担任锦好医疗实施 2022 年股票期权与限制性股票激励计划（以下简称"本次股权激励计划"或"本激励计 划"）相关事宜的专项法律顾问。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股权激励管理办法》（以下简称"《管理办法》"） ...

惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2024 年 8 月 26 日召开第 三届董事会第四次会议和第三届监事会第四次会议，分别审议通过了《关于调整公司 2022 年股权激励计划首次及预留授予股票期权行权价格的议案》，对公司 2022 年股权 激励计划（以下简称"本次激励计划"）首次及预留授予股票期权行权价格进行调整，现 将相关内容公告如下： 证券代码：872925 证券简称：锦好医疗 公告编号：2024-063 惠州市锦好医疗科技股份有限公司 关于调整公司 2022 年股权激励计划首次及预留授予股票期权行权价格 的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、本次激励计划已履行的相关审批程序 1、2022 年 3 月 25 日，公司召开第二届董事会第十五次会议，审议《关于<惠州市 锦好医疗科技股份有限公司 2022 年股权激励计划（草案）>的议案》、《关于公司 2022 年股权激励计划授予的激励对象名单的议案》、《关于制定<惠州市锦好医疗科技股份 有限公司 2022 年股权激励 ...